Tolerability and efficacy of switch from oral selegiline to orally disintegrating selegiline (Zelapar) in patients with Parkinson's disease
Phase of Trial: Phase IV
Latest Information Update: 12 Mar 2009
At a glance
- Drugs Selegiline (Primary) ; Selegiline
- Indications Parkinson's disease
- Focus Therapeutic Use
- 12 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Apr 2008 New trial record.